Generative AI is on track to shape the future of drug design

This AI-designed drug for IBD was just given to human subjects for the first time

Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

FDA Deploying AI to Accelerate Drug Approvals

In a sweeping internal reform, the U.S. Food and Drug Administration (FDA) has launched its first agency-wide deployment of artificial intelligence for drug review. Last Friday, Commissioner Dr. Martin Makary announced that all FDA centers must “aggressively” and “immediately” integrate generative AI by June 30, following the agency’s first pilot review using the technology. “I ... The post FDA Deploying AI to Accelerate Drug Approvals appeared …

Generating 3D small binding molecules using shape-conditioned diffusion models with guidance

Drug development is a critical but notoriously resource- and time-consuming process. Traditional methods, such as high-throughput screening, rely on opportunistic trial and error and cannot ensure optimal precision design. To overcome these challenges, generative artificial intelligence methods have emerged to directly design molecules with desired properties. Here we develop a generative artificial intelligence method DiffSMol for drug discover…

Generative AI is on track to shape the future of drug design

Using advanced artificial intelligence, researchers have developed a novel method to make drug development faster and more efficient.

AI in Clinical Practice Must Be Gradually Adapted

The NCPDP’s Executive Vice President of Innovation & Standards joins Drug Topics to discuss how AI has been making itself known within the pharmacy profession.

Systems-level drug design could point the way to more effective therapies for aging and chronic disease – RamaOnHealthcare

A new study published in Aging Cell demonstrates that artificial intelligence can be used not just to accelerate drug discovery, but to fundamentally